The University of Cincinnati is delving into a critical health issue impacting the diabetes community with a considerable $2.6 million research grant. The recipient of this generous federal funding is none other than Konstantinos Drosatos, PhD, an Ohio Eminent Scholar and professor at the College of Medicine's Department of Pharmacology, Physiology and Neurobiology. Dr. Drosatos is set to lead a comprehensive four-year investigation into diabetic cardiomyopathy, a form of heart disease that's more silent but just as lethal as other diabetes-related conditions. In a statement posted on the University of Cincinnati's news site, Drosatos emphasized the gravity of the condition: "This condition doesn’t get as much attention as other complications of diabetes, but it can be just as deadly."
With the backing of the National Heart, Lung, and Blood Institute, the Drosatos Lab aims to closely scrutinize the GLUT1 protein and its role in sugar metabolism within heart cells. Diabetic cardiomyopathy isn't typically linked to the usual suspects like high blood pressure or blocked arteries, instead, it spawns from changes at a cellular level caused by excess glucose. This project seeks not only to better understand how these changes come to be but also to find a way to intervene effectively. Sobuj Mia, PhD, an assistant research professor collaborating with Drosatos, outlined the core issue to UC: "Glucotoxicity, or sugar-related damage, and lipotoxicity, which is fat-related damage, both contribute to the weakening of the heart’s structure and function and can lead to heart failure." According to the University of Cincinnati News.
The research pivots on the hypothesis that overactivity of GLUT1 in diabetes patients leads to an overload of glucose, strikingly similar to a car's engine being flooded with fuel. This doesn't translate into more energy for the heart but rather initiates a cascade of detrimental effects that eventually undermine the heart's ability to pump blood efficiently. The study's findings could potentially open up new therapeutic strategies to prevent heart failure among those with diabetes, a demographic steadily on the rise globally.
